ALA-10 is active at a dose of approximately 1.2mgorally in humans and has around 7 to 10% of thepotency ofLSD.[1][2][3][9][10] It produces LSD-like psychic effects.[2][10] It is said to have a quickeronset and shorterduration than LSD.[2][10] For comparison,LAE-32, has a dose range of 0.5 to 1.6mg, about 5 to 10% of the activity of LSD, and a likewise faster onset and shorter duration than LSD.[1][2][3][9] Both ALA-10 and LAE-32 are said to produce only slight or weakhallucinogenic effects.[11] ALA-10 is around 15-fold less potent thanALD-52 (1-acetyl-LSD), which is roughlyequipotent with LSD.[1][2][3]
^abcdefgFanchamps A (1978)."Some Compounds With Hallucinogenic Activity". In Berde B, Schild HO (eds.).Ergot Alkaloids and Related Compounds. Handbook of Experimental Pharmacology (HEP). Vol. 49. Berlin, Heidelberg: Springer Berlin Heidelberg. pp. 567–614.doi:10.1007/978-3-642-66775-6_8.ISBN978-3-642-66777-0. Archived fromthe original on 30 March 2025.I-Acetyl-lysergic acid ethylamide (ALA 10, No. 36g), the acetylated analogue of LAE 32, exhibits 7% of the psychotomimetic effect of LSD (ISBELL et a!., 1959a). Its antiserotonin potency on the isolated rat uterus is 40% of that of LSD (thus three times stronger than LAE 32), whereas its pyretogenic effect in rabbits is only 1 % of the LSD action (Sandoz Res. Lab., 1958). [...] Also if applied to the less potent lysergic acid ethylamide or pyrrolidide, the 1-substitution (ALA 10, MLA 74, MPD75) only slightly affects the psychotomimetic activity of the parent compounds LAE 32 and LPD 824. [...] Table 2. Psychotomimetic activity and some pharmacodynamic effects of structural analogues of LSD [...] The monosubstituted ethyl-analogues LAE32, ALA 10, MLA 74 are psychotomimetic, but about 10-20 times weaker than the corresponding diethylamides LSD, ALD 52, and MLD41. [...]
^Rutschmann J, Stadler PA (1978). "Chemical Background". In Berde B, Schild HO (eds.).Ergot Alkaloids and Related Compounds. Handbook of Experimental Pharmacology (HEP). Vol. 49. Berlin, Heidelberg: Springer Berlin Heidelberg. pp. 29–85.doi:10.1007/978-3-642-66775-6_2.ISBN978-3-642-66777-0.
^Elliott SP, Holdbrook T, Brandt SD (May 2020). "Prodrugs of New Psychoactive Substances (NPS): A New Challenge".Journal of Forensic Sciences.65 (3):913–920.doi:10.1111/1556-4029.14268.PMID31943218.Recently, a number of LSD derivatives and analogues have been investigated, namely 1-acetyl-LSD (1A-LSD, ALD-52), [...] (46-52) (Figure 1B). A biotransformation has been observed in lysergamides acylated at the indole nitrogen that in turn produce the corresponding "core" drug of LSD or ETH-LAD (52). Therefore, 1P-LSD, 1B-LSD and ALD-52 are all prodrugs of LSD and 1P-ETH-LAD is a prodrug of ETH-LAD. All of these drugs have been discussed in Internet drug forums and are currently available for purchase online (53-56). Although ALD-52 was known to be psychoactive in humans for a long time (57), the formation of LSD both in vitro and in vivo (rats) has only been confirmed recently (51,57).
^Schifano F, Vento A, Scherbaum N, Guirguis A (2023). "Stimulant and hallucinogenic novel psychoactive substances; an update".Expert Review of Clinical Pharmacology.16 (11):1109–1123.doi:10.1080/17512433.2023.2279192.hdl:2299/27223.PMID37968919.
^abJacob P, Shulgin AT (1994). "Structure-activity relationships of the classic hallucinogens and their analogs".NIDA Research Monograph.146:74–91.PMID8742795.
^Keup W (1970)."Structure-Activity Relationship among Hallucinogenic Agents".Origin and Mechanisms of Hallucinations. Boston, MA: Springer US. pp. 345–376.doi:10.1007/978-1-4615-8645-6_29.ISBN978-1-4615-8647-0. Retrieved12 October 2025.A relation in the same direction might exist between the two N-monoethyl analogues ALA-10 and MLA-74, if judged by their LD50; both are only slightly psychotomimetic. The unsubstituted N-monoethyl analogue of LSD itself is a weak hallucinogen only [122].
